Clinical trials: Colorectal Adenocarcinoma
Rectal Cancer, Rectum Neoplasm
Effect of Pelvic Rehabilitation After Low Anterior Resection for Cancer Rectum. - A Randomised Controlled Trial
Study Purpose: This study aims to understand how pelvic floor rehabilitation (PFR) after low anterior resection (LAR) surgery for rectal cancer affects bowel control and quality of life compared to usual care.
- Conditions
- Rectal Cancer, Rectum Neoplasm, Rectal Neoplasms, Rectal Adenocarcinoma
- Trial name
- PERECARE (NCT06524362)
- Testing
- Pelvic Floor Physiotherapy (PFR), Conventional group
- Where
- India
- Volunteers
- 77 people
- Sponsor
- GEM Hospital & Research Center
Anal Cancer, Carcinoma of the Appendix
Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00654160
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Mayo Clinic
NRG1 Fusion, Pancreatic Cancer
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Merus is providing single patient/named access to the HER2/HER3 bispecific antibody, MCLA-128, to patients with advanced NRG1-fusion positive solid tumor under this early access program who are ineligible for an ongoing MCLA-128…
- Conditions
- NRG1 Fusion, Pancreatic Cancer, Non Small Cell Lung Cancer, Solid Tumor, Unspecified, Adult
- Trial name
- NCT04100694
- Testing
- MCLA-128
- Sponsor
- Merus B.V.
Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
This is a Phase 1, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of etrumadenant (AB928) in combination with…
- Conditions
- Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer, Colorectal Cancer
- Trial name
- NCT03629756
- Testing
- Etrumadenant, Zimberelimab
- Where
- 15 sites in United States, Australia
- Volunteers
- 48 people
- Sponsor
- Arcus Biosciences, Inc.
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Advanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma
Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
This phase I trial investigates the side effects and best dose of talazoparib when given together with trifluridine/tipiracil for the treatment of patients with colorectal or gastroesophageal cancer that has spread to nearby…
- Conditions
- Advanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT04511039
- Testing
- Trifluridine and Tipiracil Hydrochloride, Talazoparib Tosylate
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Roswell Park Cancer Institute
Colon Adenocarcinoma
Study of the Immune Response in Colon Adenocarcinoma
Duration of each part of the study per patient: Screening: From 1 to 4 weeks Sampling period (blood and tissue): 1 day Follow-up by patient: 60 months Total study duration by patient: 84 months Total inclusion duration: 24 months…
- Trial name
- IMCO (NCT03015038)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8
Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial
This phase I trial studies the side effects and best dose of papaverine (PPV) when given together with radiation therapy (RT) and tests how well it works in treating patients with rectal cancer that has spread to nearby tissue or…
- Conditions
- Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
- Trial name
- NCT06834126
- Testing
- Biospecimen Collection, Computed Tomography, Consolidation Therapy
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- City of Hope Medical Center
Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
This phase I pilot trial studies the side effects of cluster of differentiation 8 (CD8)+ T cells in treating patients with gastrointestinal tumors that have spread to other places in the body.
- Conditions
- Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Digestive System Carcinoma
- Trial name
- NCT02757391
- Testing
- Adoptive Immunotherapy, Aldesleukin, Cyclophosphamide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer, Adenocarcinoma of the Colon
A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer
The purpose of this study is find out whether the combination of trastuzumab deruxtecan (T-DXd) and cetuximab is an effective treatment for participants with metastatic and/or unresectable colorectal cancer that expresses low…
- Conditions
- Colorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
- Trial name
- NCT07691489
- Testing
- Fam-Trastuzumab Deruxtecan-Nxki
- Where
- 7 sites in United States
- Volunteers
- 27 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
HCC - Hepatocellular Carcinoma, Colorectal Cancer Metastatic
ctDNA Monitoring in Patients With HCC and mCRC
"Liquid biopsy" is a collective term that refers to the analysis of cancer-derived biomarkers isolated from the biological fluids of cancer patients.
- Trial name
- NCT07001085
- Testing
- Tumor Tissue Collection and NGS, Blood Collection for Plasma ctDNA, ctDNA Mutation Analysis via ddPCR
- Where
- Poland
- Volunteers
- 300 people
- Sponsor
- Medical University of Warsaw
Colorectal Cancer
Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether fluorouracil and leucovorin plus irinotecan is more effective than fluorouracil…
- Trial name
- NCT00004885
- Testing
- FOLFIRI regimen, fluorouracil, irinotecan hydrochloride
- Where
- 57 sites in Austria, Belgium and 7 more
- Volunteers
- 430 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Colon Adenocarcinoma, Neuropathic Pain
Impact of Probiotics on Neuropathy Induced by Adjuvant Chemotherapy in Patients With Colon Cancer.
The pbjective of this study is to assess the impact of a multi-strain bacteria probiotic OXXYSLAB® on the reduction of oxaliplatin-induced peripheral neuropathy in patients with stage III colon cancer receiving FOLFOX or XELOX…
- Trial name
- PROBIOCOL (NCT07733817)
- Testing
- PROBIOTIC SUPPLEMENTATION BY OXXYSLAB®
- Where
- 7 sites in France
- Volunteers
- 130 people
- Sponsor
- Centre Francois Baclesse
Cancer
Gene Therapy in Treating Patients With Cancer
RATIONALE: Inserting a gene that has been created in the laboratory into a person's white blood cells may make the body build an immune response to kill cancer cells.
- Trial name
- NCT00004178
- Testing
- therapeutic autologous lymphocytes
- Where
- United States
- Sponsor
- Roger Williams Medical Center
Anal Carcinoma, Bladder Carcinoma
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the tracer (68Ga-FAPi-46) accumulates in normal and…
- Conditions
- Anal Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma
- Trial name
- NCT07118176
- Testing
- Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Colorectal Cancer, Cholangiocarcinoma
A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
This study is being done to answer the following question: Is the combination of the Medtronic pump and the Codman catheter device a safe alternative to the C3000 Codman pump for delivering chemotherapy directly into the liver of…
- Trial name
- NCT04668976
- Testing
- Medtronic pump and Codman catheter, Floxuridine (FUDR), Gemcitabine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Benaroya Research Institute
Ewing Sarcoma, Colorectal Adenocarcinoma
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
- Trial name
- NCT03715933
- Testing
- INBRX-109, Irinotecan, Temozolomide
- Where
- 37 sites in United States, France and 4 more
- Volunteers
- 411 people
- Sponsor
- Inhibrx Biosciences, Inc
Motor Function, Cognitive Function
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA.
- Conditions
- Motor Function, Cognitive Function, Contrast Media
- Trial name
- ODYSSEY (NCT04373564)
- Testing
- Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain
- Where
- 51 sites in United States, Brazil and 6 more
- Volunteers
- 2,076 people
- Sponsor
- Guerbet
Breast Carcinoma, Colorectal Adenocarcinoma
Vaccine Response With NT-I7
Background: People with cancer, and especially older people, have a weakened immune system (the defense system of the body). This is often caused by the treatments for cancer.
- Conditions
- Breast Carcinoma, Colorectal Adenocarcinoma, Bladder Carcinoma
- Trial name
- NCT04054752
- Testing
- Recombinant human IL-7-hyFc (NT-I7), Vaccine sequence 1, Vaccine sequence 2
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Rectal Adenocarcinoma
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
feasibility of using a diffusion sequence of a MRgRT system as an early marker of treatment response during nRCT of rectal adenocarcinoma.
- Trial name
- DWI_RECT_MRGRT (NCT03961776)
- Testing
- MRI-guided radiotherapy by on-board DWI sequences
- Where
- 2 sites in United States, France
- Volunteers
- 39 people
- Sponsor
- Institut Paoli-Calmettes
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.